Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 15401

1.

Limitations to the Dutch cannabis toleration policy: Assumptions underlying the reclassification of cannabis above 15% THC.

Van Laar M, Van Der Pol P, Niesink R.

Int J Drug Policy. 2016 Feb 26. pii: S0955-3959(16)30020-2. doi: 10.1016/j.drugpo.2016.02.011. [Epub ahead of print]

PMID:
27471078
2.

Cannabis and cannabinoids.

[No authors listed]

Med Lett Drugs Ther. 2016 Aug 1;58(1500):97-8. No abstract available.

PMID:
27466748
3.

Assessing the Validity of Online Drug Forums as a Source for Estimating Demographic and Temporal Trends in Drug Use.

Paul MJ, Chisolm MS, Johnson MW, Vandrey RG, Dredze M.

J Addict Med. 2016 Jul 26. [Epub ahead of print]

PMID:
27466069
4.

Cannabis Use Surveillance By Sweat Analysis.

Gambelunghe C, Fucci N, Aroni K, Bacci M, Marcelli A, Rossi R.

Ther Drug Monit. 2016 Jul 25. [Epub ahead of print]

PMID:
27465974
5.

Stratifying delays for assessment by type of substance to improve the probability of attendance in outpatient services.

Simioni N, Rolland B, Labreuche J, Ramdane N, Cottencin O.

Drug Alcohol Depend. 2016 Jul 20. pii: S0376-8716(16)30209-5. doi: 10.1016/j.drugalcdep.2016.07.012. [Epub ahead of print]

PMID:
27465970
6.

One Minute of Marijuana Secondhand Smoke Exposure Substantially Impairs Vascular Endothelial Function.

Wang X, Derakhshandeh R, Liu J, Narayan S, Nabavizadeh P, Le S, Danforth OM, Pinnamaneni K, Rodriguez HJ, Luu E, Sievers RE, Schick SF, Glantz SA, Springer ML.

J Am Heart Assoc. 2016 Jul 27;5(8). pii: e003858. doi: 10.1161/JAHA.116.003858.

7.

Determination of 21 drugs in oral fluid using fully automated supported liquid extraction and UHPLC-MS/MS.

Valen A, Leere ÅM, Strand DH, Skari R, Berg T.

Drug Test Anal. 2016 Jul 28. doi: 10.1002/dta.2045. [Epub ahead of print]

PMID:
27464485
8.

Early Survey Results from the Minnesota Medical Cannabis Program.

McGriff D, Anderson S, Arneson T.

Minn Med. 2016 Jun;99(4):18-22.

PMID:
27464390
9.

Investigation of a recently detected 11-nor-9-carboxy-Δ9-tetrahydrocannabinol isomer: Studies on the degradation of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol glucuronide.

Hanisch S, Paulke A, Toennes SW.

J Pharm Biomed Anal. 2016 Jul 14;129:294-298. doi: 10.1016/j.jpba.2016.07.019. [Epub ahead of print]

PMID:
27448313
10.

A Test-Replicate Approach to Candidate Gene Research on Addiction and Externalizing Disorders: A Collaboration Across Five Longitudinal Studies.

Samek DR, Bailey J, Hill KG, Wilson S, Lee S, Keyes MA, Epstein M, Smolen A, Miller M, Winters KC, Hawkins JD, Catalano RF, Iacono WG, McGue M.

Behav Genet. 2016 Jul 21. [Epub ahead of print]

PMID:
27444553
11.

Effects of Cannabis Use on Human Behavior-Reply.

Volkow ND.

JAMA Psychiatry. 2016 Jul 27. doi: 10.1001/jamapsychiatry.2016.1332. [Epub ahead of print] No abstract available.

PMID:
27463420
12.

Effects of Cannabis Use on Human Behavior: A Call for Standardization of Cannabis Use Metrics.

Solowij N, Lorenzetti V, Yücel M.

JAMA Psychiatry. 2016 Jul 27. doi: 10.1001/jamapsychiatry.2016.1329. [Epub ahead of print] No abstract available.

PMID:
27463333
13.

Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.

Nia AB, Medrano B, Perkel C, Galynker I, Hurd YL.

J Psychopharmacol. 2016 Jul 26. pii: 0269881116658990. [Epub ahead of print]

PMID:
27462088
14.

Qualitative research in Spanish cannabis social clubs: "The moment you enter the door, you are minimising the risks".

Belackova V, Tomkova A, Zabransky T.

Int J Drug Policy. 2016 Apr 20. pii: S0955-3959(16)30101-3. doi: 10.1016/j.drugpo.2016.04.009. [Epub ahead of print]

PMID:
27461986
15.

The US as an example of how not to legalize marijuana?

Caulkins JP, Kilmer B.

Addiction. 2016 Jul 26. doi: 10.1111/add.13498. [Epub ahead of print] No abstract available.

PMID:
27460874
16.

Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.

Russo M, De Luca R, Torrisi M, Rifici C, Sessa E, Bramanti P, Naro A, Calabrò RS.

Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):3127-33.

PMID:
27460745
17.

No Smoke without Tobacco: A Global Overview of Cannabis and Tobacco Routes of Administration and Their Association with Intention to Quit.

Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR.

Front Psychiatry. 2016 Jul 5;7:104. doi: 10.3389/fpsyt.2016.00104. eCollection 2016.

18.

Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.

Abouchedid R, Ho JH, Hudson S, Dines A, Archer JR, Wood DM, Dargan PI.

J Med Toxicol. 2016 Jul 25. [Epub ahead of print]

PMID:
27456262
19.

Integrating environmental and self-report data to refine cannabis prevalence estimates in a major urban area of Switzerland.

Been F, Schneider C, Zobel F, Delémont O, Esseiva P.

Int J Drug Policy. 2016 Jun 15;36:33-42. doi: 10.1016/j.drugpo.2016.06.008. [Epub ahead of print]

PMID:
27455466
20.

Acute effects of cannabis on breath-holding duration.

Farris SG, Metrik J.

Exp Clin Psychopharmacol. 2016 Aug;24(4):305-12. doi: 10.1037/pha0000075.

PMID:
27454678
Items per page

Supplemental Content

Loading ...
Write to the Help Desk